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Abstract
Fatty acid 2-hydroxylase (FA2H) is the enzyme responsible for the hydroxylation of free fatty acids prior to their
incorporation into 2-hydroxylated sphingolipids, which are the major constituents of the myelin leaflet. Mutated
FA2H has been associated with neurodegenerative diseases. Decreased FA2H activity was demonstrated only in
vitro, but not in patient tissues. In this study we characterized the 2-hydroxylated sphingomyelin (SM) profiles in
blood and fibroblasts from patients harboring a deleterious FA2H mutatation, and found that hydroxylated fatty
acid sphingomyelin is present in normal amounts in patient lymphocytes, but decreased to a different extent in
fibroblasts and erythrocytes.
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Background
A compact myelin sheet surrounding the axon is essen-
tial for correct nerve conduction [1]. Myelin is com-
posed of over 70% lipids, the most abundant of which
are the galactolipids galactosylceramide (GalC) and its
sulfated form, sulfatide. As more than fifty percent of
GalC and sulfatide are hydroxylated at the C2 position
on the fatty acid (FA) moiety, it has been estimated that
approximately twenty five percent of the outer leaflet
lipids in myelin are hydroxylated [2,3]. Based on studies
of model membranes, hydroxylation likely contributes to
the stability of myelin by virtue of the hydrogen bonding
between the hydroxy groups, the galactose head group
and the polar part of the ceramide backbone [4].
The 2- hydroxylation of sphingolipids [for review, see
[5]] occurs during de novo ceramide synthesis and is
catalyzed by the enzyme fatty acid 2-hydroxylase
(FA2H), a membrane-bound protein containing a cyto-
chrome b5-like heme-binding domain responsible for
the redox activity, and a sterol desaturase domain [6].
The products of FA2H are free 2-hydroxy fatty acids
(OHFA), which are subsequently incorporated into cera-
mide, the precursor of galactosylceramide [7]. FA2H-
deficient mice lacking hydroxylated fatty acids in the
central and peripheral nervous system had normal neu-
ronal development, but showed late onset axon and
myelin sheet degeneration [8] and exhibited CNS dys-
function [9].
Mutations in the human FA2H gene were identified in
patients with autosomal recessive leukodystrophy char-
acterized by childhood (4-5 y) onset spasticity, dystonia
and white matter degeneration. In seven patients, the
desaturase domain was disrup t e db yas p l i c es i t em u t a -
tion causing the skipping of exons 5 and 6 while a mis-
sense mutation in a conserved residue was detected in
the other two patients [10]. Recently, mutated FA2H
was also found to be the underlying cause of a compli-
cated hereditary spastic paraplegia (SPG35) [11], and
neurodegeneration with brain iron accumulation [12].
Although in vitro transfection studies of mutated FA2H
disclosed reduced hydroxy fatty acid synthesis, decreased
enzymatic activity was not demonstrated in patients. In
fact, tetracosanoic acid hydroxylating activity in patient
fibroblasts was indistinguishable from that of normal
controls [10]. Moreover, the impact of defective FA2H
on fatty acid composition in patients is (to our knowl-
edge) unknown. The aim of this study was to
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mutation on the fatty acid and hydroxy fatty acid sphin-
gomyelin profiles in patient’s blood and fibroblasts.
Methods
Cell culture reagents were obtained from Biological
Industries, Beit HaEmek, Israel. Hisopaque and all other
reagents were from Sigma-Aldrich, Israel.
Subjects
B l o o df r o mt w op a t i e n t sa n df i b r o b l a s t sf r o mo n e
patient harboring the FA2H c.786+1G®Am u t a t i o n
(family 1, described by Edvardsson et al [10] and from
three controls were obtained with informed consent and
approval from the local IRB.
Lymhocyte isolation
Lymphocytes were isolated from whole blood (EDTA
anti-coagulant) using Histopaque-1077 according to the
manufacturer’s instructions. The resulting pellet was
lyophilized prior to lipid analysis.
Erythrocyte membrane preparation
Erythrocyte membranes were prepared from whole
blood collected with heparin as anti-coagulant. The
blood was spun at 1000 × g for 10 min, the plasma was
removed and the erythrocytes were washed three times
with twice their volume of saline. Subsequently, cells
were hemolyzed in 5 ml of water then spun at 12000 ×
g for 10 minutes. The membranes were washed twice
with water and lyophilized prior to lipid analysis.
Cell culture
Primary fibroblasts were grown in DMEM (high glu-
cose) supplemented with 15% fetal calf serum in the
presence of penicillin and streptomycin. Confluent cells
were harvested by trypsinization, washed with phosphate
buffered saline (PBS) and lyophilized prior to lipid
analysis.
Lipid analysis
Lipid analysis was performed at the Lipidomics Core of
the Medical University of South Carolina using HPLC/
MS-MS as previously described [13,14]. All values are
reported normalized to mg protein as determined using
the Lowry method [15].
RT-PCR
Total RNA from lymphoblasts was prepared using TRI
reagent (Sigma Aldrich) and equal amounts were reverse
transcribed using ImProm-II (Promega, Wisconsin,
USA) reverse transcriptase kit with a hexamer mixture
as the template primer according to the manufacturer’s
instructions. Primer sequences for PCR analysis available
upon request.
Results and discussion
We have previously shown that the c.786+1G®Am u t a -
tion causes mis-splicing leading to skipping of exons 5
and 6 in fibroblasts. RT-PCR was perfomed in order to
verify the exon skipping in lymphocytes. The expected
426bp shorter transcript, obtained in the patient, corro-
borated the exon skipping as shown in Figure 1A.
Subsequently we proceeded to investigate the sphingo-
myelin (SM) profiles in these cells as well as in erythro-
cyte membranes and fibroblasts (Figure 1B-C).
The total SM-fatty acid content in patient fibroblasts
and lymphocytes was not significantly different from
that of control subjects, while patient erythrocytes had a
relatively higher SM-fatty acid content (Figure 1B). SM-
hydroxy fatty acid content in patient lymphocytes was
not significantly different from that of the controls,
however it was reduced by 50% in patient fibroblasts
and increased in patient erythrocytes (Figure 1 C). The
decrease in SM-hydroxy fatty acid content in fibroblasts
was especially evident when the ratio of SM-hydroxy
fatty acid to SM-fatty acid was calculated. In patient ery-
throcytes this ratio was also significantly decreased as
SM-hydroxy fatty acids were decreased relative to SM-
fatty acids Figure 1D).
The distribution of the SM-fatty acid (Figure 2A, B)
and SM-hydroxy fatty acids (Figures 2C, 2D) by chain
length was investigated. C16 is by far the most abundant
fatty acid in all cell types. No differences were seen
between patient and control lymphocytes. SM-C16 fatty
acid content was slightly increased in patient fibroblasts,
and the levels of most SM-fatty acids were increased in
patient erythrocytes. In all cell types, in control as well
as patient, the distribution of SM-hydroxy fatty acids
d o e sn o tm i r r o rt h a to ft h e i rf a t t ya c i dc o u n t e r p a r t .I n
lymphocytes, SM-OHC18 is the most abundant species,
and the distribution of SM-hydroxy fatty acids is the
same in the patient and the control. However, patient
fibroblasts contain approximately 50% of SM-OHC16
and SM-OHC18 of the control values, and all the other
SM-hydroxy fatty acid levels were significantly lower.
The patient erythrocytes had an elevated content of all
SM-hydroxy fatty acids, but with a significant increase
of SM-OHC18 vs SM-OHC16.
The fraction of hydroxylated fatty acid relative to fatty
acid (OHFA-SM/FA-SM) of the same chain length was
calculated (Figure 2E, 2F). This ratio is the same for
both control and patient lymphocytes, where the ratio is
highest for C18. In contrast, in patient fibroblasts, the
fraction of hydroxylated C20:1 is only 1/10 that of the
control value, with reductions for C18 and C20 as well.
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Page 2 of 5C20 is the most hydroxylated saturated fatty acid in
both control and patient, whereas C20:1 is the most
hydroxylated monounsaturated acid in the controls and
C24:1 the most hydroxylated monounsaturated acid in
the patient. In erthrocytes, the ratio is decreased for the
patient vs the control for all chain lengths, most notice-
ably for C20 and C22, with C20 and C24:1 the most
heavily hydroxylated acids.
As SM is the major sphingolipid in human cultured
fibroblasts [16], and taking into account the limited
amount of sample, we focused our studies on this sphin-
golipid in cells obtained from patients using minimally
invasive sampling. The lack of difference in the SM fatty
acid and hydroxy fatty acid profile between patient and
control lymphocytes was unexpected. Apparently the
lack of FA2H as demonstrated by RT-PCR had no
effect. On the other hand, SM hydroxy fatty acid con-
tent in fibroblasts was clearly decreased, with respect to
both the total content and the fraction of hydroxylated
SM. The high OHFA content but low OHFA-SM/FA-
SM ratio in erythrocytes suggests an imbalance, rather
than a quantitative change. The distribution of OHFA
according to chain length is different in the patient and
control fibroblasts, with C20:1 being the most hydroxy-
l a t e da c i di nt h ec o n t r o l sa n dC 2 4 : 1t h em o s th y d r o x y -
lated in the patient.
The results we obtained for FA content and distribu-
tion confirm previous results [16] however in that
paper the authors did not find any hydroxy fatty acids.
They conclude that if present, they must be in
amounts below their detection limit of a few pmoles.
This is certainly not in agreement with the results pre-
sented here. The discrepancy could be due to differ-
ences in the sample preparation as well as analytical
conditions.
The characterization of the FA and OHFA profiles was
carried out also to identify differences between controls
and patients which could possibly form the basis for a
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Figure 1 Lymphocyte FA2H patient transcript and total FA-SM/OH-SM profiles.A ,L a n eCs h o w st h et r a n s c r i p to b t a i n e di nc o n t r o l
lymphocytes using the FA2H primer and lane P shows the shorter transcript obtained in patient lymphocytes. B, Total level of FA-SM in control
and patient fibroblasts, lymphocytes and erythrocytes was quantitated by HPLC/MS-MS. C, Total level of OHFA-SM in control and patient
fibroblasts, lymphocytes and erythrocytes was quantitated by HPLC/MS-MS. D, The ratio of the total OHFA-SM content divided by the total FA-
SM content was calculated (mean of 2 experiments +/- SD).
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Page 3 of 5biochemical diagnostic test. The most significant differ-
ence was found in the relative decrease in OHFA-SM rela-
tive to FA-SM content in patient erythrocytes vs control.
In cases where a skin biopsy is performed and fibroblasts
are available, the decrease in saturated OHFA content
coupled with the favoring of OHC24:1 in patients vs
OHC20:1 in controls could also serve as a marker.
Although genetic analysis is more feasible, FA-SM analysis
could complement the molecular data and provide valu-
able information where genetic analysis is uninformative.
It is somewhat surprising that patient cells still contain
a measurable amount of hydroxy fatty acids at all, consid-
ering the deleterious nature of the mutation in the FA2H
gene. This would suggest presence of other enzyme/s
with overlapping substrate specificity with FA2H. In
fibroblasts and erythrocytes, which show a difference
between the patient and the control, the 2-hydroxylating
activity may be due to FA2H and to an additional enzyme
with a different chain length preference. In lymphocytes,
FA2H may be absent altogether while the proposed other
enzyme performs the FA2-hydroxylation. Notably we
were unable to detect any FA2H enzymatic activity in
normal lymphocytes (results not shown).
Conclusions
We conclude that OHFA-SM is decreased in patient
fibroblasts and erythrocytes. Differences in FA-SM and
OH-SM between patients and controls could serve as
the basis for a diagnostic test.
List of abbreviations
FA2H: Fatty acid 2-hydroxylase; FA: Sphingomyelin:SM, Fatty acid; OHFA:
Hydroxy fatty acids; GalC: galactosylceramide.
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Figure 2 Levels of saturated and unsaturated FA-SM and OHFA-SM in the range C14-C24 in fibroblasts, lymphocytes and erythrocytes
of control subjects and in patients were quantitated by HPLC/MS-MS. A, Saturated FA-SM. B, Unsaturated FA- SM.C, Saturated OHFA-SM. D,
Unsaturated OHFA-SM. E, Ratio saturated OHFA -SM/FA-SM. F. Ratio unsaturated OHFA -SM/FA- SM (mean of 2 experiments +/- SD).
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